NCT00369343 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women | Biotech Hunter

Enrollment

381

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

July 31, 2008

Conditions

DepressionDepressive DisorderDepressive Disorder, Major

Interventions

DRUG

Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)

DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks

DRUG

Placebo

Placebo, daily (QD), tablet form, treatment period up to 8 weeks

Trial Locations (37)

11235

Brooklyn

19131

Philadelphia

20852

Rockville

23229

Richmond

23230

Richmond

29926

Hilton Head Island

30080

Smyrna

30308

Atlanta

30328

Sandy Springs

31406

Savannah

32789

Winter Park

33133

Miami

33613

Tampa

34208

Bradenton

35226

Birmingham

43623

Toledo

44122

Beachwood

45408

Dayton

46202

Indianapolis

47802

Terre Haute

53223

Brown Deer

58701

Minot

60634

Chicago

68131

Omaha

71101

Shreveport

72223

Little Rock

72762

Springdale

73118

Oklahoma City

74135

Tulsa

77007

Houston

78756

Austin

83404

Idaho Falls

92103

San Diego

94305

Palo Alto

98105

Seattle

06320

New London

08002

Cherry Hill

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY